# Study of Verinurad in Heart Failure With Preserved Ejection Fraction

Study · id `cardio:ct-nct04327024` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04327024](<https://clinicaltrials.gov/study/NCT04327024>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04327024

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

## Technical summary

Registry record NCT04327024. Randomized; triple masking; primary purpose treatment. Start 2020-05-19 (actual); primary completion 2022-04-29 (actual). Results posted on 2023-06-29.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 159 participants (enrolled count; ClinicalTrials.gov record NCT04327024, source copy `cardio:ctgov-nct04327024-2023-06-29`, retrieved 2026-10-26)
- Started: 2020-05-19 (actual) (ClinicalTrials.gov record NCT04327024, source copy `cardio:ctgov-nct04327024-2023-06-29`, retrieved 2026-10-26)
- Primary completion: 2022-04-29 (actual) (ClinicalTrials.gov record NCT04327024, source copy `cardio:ctgov-nct04327024-2023-06-29`, retrieved 2026-10-26)
- Completion: 2022-04-29 (actual) (ClinicalTrials.gov record NCT04327024, source copy `cardio:ctgov-nct04327024-2023-06-29`, retrieved 2026-10-26)
- Results first posted: 2023-06-29 (ClinicalTrials.gov record NCT04327024, source copy `cardio:ctgov-nct04327024-2023-06-29`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Bulgaria; Canada; Germany; Mexico; Poland; Russia; Slovakia; South Korea (ClinicalTrials.gov record NCT04327024, source copy `cardio:ctgov-nct04327024-2023-06-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04327024-2023-06-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Verinurad in Heart Failure With Preserved Ejection Fraction
- Acronym: AMETHYST
- Condition: Heart Failure With Preserved Ejection Fraction (HFpEF)
- Intervention (Drug): Verinurad
- Intervention (Drug): Allopurinol
- Intervention (Drug): Placebo for verinurad
- Intervention (Drug): Placebo for allopurinol
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial (`cardio:pubmed-39141378`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d72023ef5ba73bf245057afac0f3416684e5d25221841dcb20ae82b70b3db6ee
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
